Current Hemophilia Research: Gene Therapy, Novel Treatments, and Health Equity

Key research priorities:

1. Genetic Understanding

• Genotype-phenotype correlations; modifiers of severity.
• Epigenetic regulation of F8/F9 expression.

2. Gene Therapy Advancement

• AAV vector optimization (tropism, immunogenicity, dose reduction).
• CRISPR/Cas9 gene editing (ex vivo/in vivo correction).
• Long-term durability, insertional oncogenesis monitoring.

3. Improved Factor Delivery

• Subcutaneous, oral, or inhaled formulations.
• Personalized PK-guided dosing.

4. Alternative Therapeutic Modalities

• Non-factor therapies (TFPI inhibitors, anti-TFPI mAbs, siRNA).
• Cell-based: gene-modified hematopoietic stem cells, mesenchymal stromal cells.

5. Complication Management & Quality of Life

• Early arthropathy detection (MRI, ultrasound).
• Psychosocial interventions, pain management.

6. Global Equity

• Access in low/middle-income countries (WFH Humanitarian Aid Program).
• Capacity building, local factor production.

7. Health Economics

• Cost-effectiveness of prophylaxis vs. on-demand.
• Value-based pricing for gene therapies.

Collaborative networks (ISTH, WFH, NHF, industry) drive progress.